Glucagon-like peptide-1 receptor agonist semaglutide reduces atrial fibrillation incidence: A systematic review and meta-analysis.
Andrea SagliettoGiulio FalasconiDiego PenelaPietro FranciaArunashis SauFu Siong NgVeronica DusiDavide CastagnoFiorenzo GaitaAntonio BerruezoGaetano Maria De FerrariMatteo AnselminoPublished in: European journal of clinical investigation (2024)
Semaglutide significantly reduces the occurrence of incident AF by 42% as compared to placebo in individuals at high CV risk, mainly affected by type 2 diabetes mellitus. This effect appears to be consistent independently of the route of administration of the drug (oral or subcutaneous), the presence of underlying diabetes and BMI.
Keyphrases
- atrial fibrillation
- glycemic control
- cardiovascular disease
- type diabetes
- oral anticoagulants
- catheter ablation
- risk assessment
- left atrial
- risk factors
- left atrial appendage
- heart failure
- direct oral anticoagulants
- weight gain
- cardiovascular risk factors
- clinical trial
- emergency department
- randomized controlled trial
- metabolic syndrome
- phase iii
- skeletal muscle
- adverse drug
- insulin resistance
- adipose tissue
- mitral valve